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Objectives. The purpose of this study was to assess the effect of 
myocardial sympathetic denervation on the chamber-specific al- 
teration of beta-adrenergic signaling in left ventricular failure in 
rabbits. 
Background. Local abnormalities in sympathetic nerve termi- 
nals, including the neuronal reuptake of norepinephrine, are 
thought o be responsible for the chamber-specific regulation of 
beta-adrenergic signaling in heart failure. 
Methods. Sixteen rabbits were given 6-hydroxydopamine, 
25 mg/kg body weight intravenously on days 1 and 2 and 50 mg/kg 
intravenously ondays 7 and 8. Another 16 rabbits received vehicle. 
Aortic regurgitation was induced in eight of the 6-hydroxydopamine- 
treated and eight of the vehicle-treated rabbits on day 14. Another 
eight of the 6-hydroxydopamine-treated and ight of the vehicle- 
treated rabbits underwent a sham operation. The hearts were xcised 
for biochemical nalysis on day 21. 
Results. Hemodynamic characteristics on day 21 showed left 
ventricular failure in both the aortic regurgitation groups. The 
plasma norepinephrine concentration on day 21 was higher in 
both the aortic regurgitation groups than in the sham groups. 
The beta-adrenoceptor densities and isoproterenol plus 5'- 
guanylylimidodiphosphate-, 5'-guanylylimidodiphosphate- nd 
sodium fluoride-stimulated a enylyl cyclase activities were de- 
creased only in the failing left ventricle of the vehicle-pretreated 
aortic regurgitation group, but in both ventricles of the 
6-hydroxydopamine-pretreated aorticregurgitation group. The 
basal and forskolin-stimulated a enylyl cyclase activities were 
similar in both the aortic regurgitation groups and in the sham 
groups. 
Conclusions. Sympathetic denervation prevented chamber- 
specific alterations in beta-adrenergic signaling in acute left 
ventricular failure. Local oss of sympathetic nerve ndings, and 
especially the defective neuronal norepinephrine r uptake, are 
likely to be responsible for the chamber-specific alteration of the 
beta-adrenoceptor-G protein-adenylyl cyclase system in heart 
failure in rabbits. 
(J Am Coil Cardiol 1996;28:1314-22) 
An increase in plasma norepinephrine in patients with heart 
failure indicates a poor prognosis and is implicated as a 
cause of beta-adrenoceptor subsensitivity and downregula- 
tion in congestive heart failure (1). We previously reported 
that myocardial norepinephrine concentration and beta- 
adrenoceptor density were reduced in the left and right 
ventricles of rabbits with chronic biventricular heart failure 
produced by the prolonged administration of adriamycin. 
However, these changes occurred only in the left ventricle of 
rabbits with acute left ventricular failure induced by aortic 
regurgitation, despite a similar increase in plasma norepineph- 
rine in both models (2). Bristow et al. (3), studying the human 
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heart, demonstrated many chamber-specific beta-adrenergic 
neuroeffector abnormalities, including beta-adrenoceptor 
downregulation, tissue norepinephrine depletion and de- 
creases in adenylyl cyclase activity stimulated by isoproterenol, 
zinterol, 5'-guanylylimidodiphosphate and forskolin, occurred 
in the failing right ventricle derived from prima W pulmonary 
hypertension, while the abnormalities occurred in both ventri- 
cles with idiopathic dilated cardiomyopathy. A local abnormal- 
ity in sympathoneuronal regulation isthought to be involved in 
these phenomena. 
Delehanty et al. (4), using SH-norepinephrine tracer in 
pacing-induced heart failure, observed a significant negative 
correlation between interstitial norepinephrine and beta- 
adrenoceptor density. A local increase in interstitial norepi- 
nephrine concentration has been suggested to cause chamber- 
specific abnormalities. In fact, a local reduction of neuronal 
norepinephrine uptake has been postulated to increase the 
local interstitial norepinephrine (5,6). In contrast, he localized 
regulation of norepinephrine release by the afferent fibers that 
originate in the failing ventricle is an alternative explanation 
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Abbreviations and Acronyms 
ANOVA - analysis of variance 
cAMP - cyclic 3'.5'-adenosine monophosphatc 
EGTA - ethylene glycol-bis(bcla-ammocthyl ether)- 
N.N.N',N'-tctraacctic a id 
for chamber-specific regulation (7). Thus, the precise mecha- 
nism of the chamber-specific regulation in beta-adrenoceptor 
density is still unknown. 
Myocardial denervation can interfere with aforementioned 
neuronal function of the sympathetic nerve terminals and 
affect the chamber-specific regulation following the induction 
of acute left ventricular overload. Chemical sympathectomy by 
6-hydrovdopamine, which causes elective destruction of ad- 
renergic nerve terminals, has been reported to decrease the 
neuronal uptake of tritiated norepinephrine (8,9). We there- 
fore hypothesized that if the local release of norepinephrine is 
responsible for the chamber-specific subsensitivity of beta- 
adrenergic signaling, pretreatment with 6-hydroxydopamine 
prevents the downregulation f beta-adrenoceptor in the fail- 
ing myocardium. However, if a local defect of neuronal uptake 
of norepinephrine is responsible for the chamber specificity, a 
marked ownregulation would occur in both ventricles and the 
chamber-specific phenomenon would be abolished by pretreat- 
ment with sympathetic denervation, because sympathetic den- 
ervation by 6-hydroxydopamine induces a severe defect of 
neuronal uptake of norepinephrine in both ventricles. We thus 
investigated the effect of sympathetic denervation on the 
chamber-specific regulation in beta-adrenergic s gnaling after 
the induction of left ventricular failure by aortic regurgitation 
to assess which mechanism isresponsible for the phenomenon. 
Methods  
Animals. We studied 32 Japanese female white rabbits (3 
months old) with a body mass -3 kg. The experiments 
conformed to the "Position of the American Heart Association 
on Research Animal Use" adopted by the Association in 
November 1984. 
Chemical denervation. The agent 6-hydroxydopamine hy- 
drobromide (Sigma Chemical) was dissolved in physiologic 
saline that contained ascorbic acid (1 mg/ml). Sixteen rabbits 
were administered two doses of 6-hydroxydopamine (25mg/kg 
body weight intravenously) 24 h apart, and two doses (50 mg/kg 
intravenously) on days 7 and 8 according to the method of 
Maling et al. (10). As controls, 16 weight-matched rabbits 
received saline that contained ascorbic acid (1 mg/ml) in the 
same schedule. 
Blood sampling for plasma norepinephrine determina- 
tions. A polyethylene catheter was placed in the jugular vein 1 
week before the administration of 6-hydroxydopamine or
vehicle. A 5-ml blood sample was obtained without anesthesia 
before the initial injection and again 1 week postoperatively. 
Blood was centrifuged at 1,500g for 15 min, and plasma was 
stored at -80°C until needed for assay. The norepinephrine 
concentration was assayed by high performance liquid chro- 
matography (11). 
Induction of acute left ventricular failure. A total of 32 
rabbits were anesthetized with chloral hydrate (150 mg/kg 
intravenously). Aortic regurgitation was induced in eight rab- 
bits with 6-hydroxydopamine and in eight rabbits with vehicle 
pretreatment, aspreviously described (2). In brief, the right 
carotid artery was isolated, and the aortic root pressure was 
measured with a 5F micromanometer-tipped catheter (PC-350, 
Millar Instruments Inc.). A 5F metal catheter was then intro- 
duced into the right carotid arte U and advanced to the aortic 
root, where the motion of the aortic valve was felt through the 
catheter. The catheter was pushed toward the left ventricle and 
the aortic valve was perforated. Diastolic murmur was audible 
in this setting. Aortic pressure was again measured to assess 
the severity of aortic regurgitation; an immediate decrease in 
aortic diastolic pressure predicts the volumc overloading to the 
left ventricle (12). In the remaining eight rabbits treated with 
6-hydrovdopamine and in the eight rabbits treated with 
vehicle, the right carotid artery, was isolated and the aortic 
pressure was measured, but aortic regurgitation was not in- 
duced by a sham operation. Antibiotics were injected for the 
next 2 days. 
Hemodynamic measurements. Hemodynamic measure- 
ments were obtained 1week postoperatively in the open-chest 
condition under anesthesia with chloral hydrate. Ventilation 
was controlled through an endotracheal tube (internal diame- 
ter 4.0 ram) introduced through a tracheal incision. Tidal 
volume was adjusted to 50 ml, with a respirato~ rate of 20 
beats/min. Aortic root pressure was monitored with a 5F 
micromanometer-tipped catheter introduced from the left 
carotid artew. Aortic flow was measured with an electromag- 
netic flow probe (Nihon-Kohden, Tokyo, Japan) placed 
around the aortic root. Left ventricular pressure was moni- 
tored with a 3F mieromanometer-tipped catheter (model 
PC-330, Millar Instruments Inc.) that was introduced through 
an apical incision. The right ventricular pressure was measured 
by a Teflon catheter introduced through its free wall. Left 
ventricular diameter was measured using a pair of ultrasonic 
microcrystals attached to the anterior and posterior epicardial 
surfaces. Hemodynamic data were collected with a thermal 
array recorder (Nihon-Kohden, Tokyo, Japan) at a paper 
speed of 200 mm/s. 
Determination of ventricular mass and myocardial norepi- 
nephrine. After hemodynamic measurements were made, the 
heart was stopped by rapid injection of potassium chloride. 
The left and right ventricular free walls were isolated and 
weighed. Portions of the left and right ventricular myocardium 
were frozen with liquid nitrogen and stored at -80°C for assay 
of myocardial norepinephrine content by high performance 
liquid chromatography (11). 
Membrane preparation. Membrane fractions were pre- 
pared as described by Feldman et al. (13). Briefly, the 
myocardium was soaked in ice-cold isotonic sucrose buffer 
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(0.25 tool/liter sucrose, 1 mmol/liter potassium bicarbonate, 
1 retool/liter magnesium chloride), and the connective tis- 
sue, endocardium, epicardium and vessels were removed as 
much as possible. The myocardium was minced with scissors 
and homogenized with tissue disrupter (Physcotron, Niti- 
On, Tokyo, Japan) at a maximal speed of 10 s. For beta- 
adrenoceptor antagonist binding studies, the homogenate of
myocardium was added to an equal volume of 0.5 tool/liter 
potassium chloride and stirred for 15 min at 4°C for 
extraction of contractile proteins. After centrifugation at 
50,000g for 15 min at 4°C, the resulting pellet was resus- 
pended in 75 retool/liter of Tris hydrochloride (pH 7.5) and 
10 mmol/liter of magnesium chloride buffer and recentri- 
fuged. The final membrane pellet was resuspended in 50 mmol/ 
liter of Tris hydrochloride (pH 7.5) containing 250 retool/liter of 
sucrose and 1 retool/liter of ethylene glycol-bis(beta-aminoethyl 
ether)-N,N,N'N'-tetraacetic acid (EGTA) and stored at -80°C. 
For adenylyl cyclase assay, the homogenate of myocardium was 
centrifuged at 1,085g for 20 min at 4°C, and the resulting pellet 
was washed twice more by the same procedure and stored at 
-80°C until assay. 
Assay of beta-adrenoceptors and beta-adrenoceptor sub- 
types. The protein concentration of membrane samples was 
determined as previously described (14) and then adjusted to 
0.3 mg/ml. The density of myocardial beta-adrenoceptors was 
determined by a ligand binding assay with iodine-125 (125I) 
iodocyanopindolol (Amersham, Tokyo, Japan). Twenty-five 
microliters of 10 different concentrations of 125I iodocyanopin- 
dolol (30 to 800 pmol/liter), together with 25 ~1 of 1.6 × 10 -6 
tool/liter of propranolol or Tris ascorbic acid buffer, was added 
to 100/~l of membrane sample. After incubation at 30°C for 
120 rain, the reaction was terminated by addition of 750/A of 
ice-cold Tris buffer. The reaction mixture was filtered through 
Whatman GF/C glass fiber filters presoaked in 0.5% polyeth- 
ylenimine solution, and then washed twice with 5 ml of Tris 
buffer. Filter-bound radioactivity was counted using a gamma 
counter (model ARC-600, Aloka Inc., Tokyo, Japan) with an 
efficiency rate of 76.5%. Specific binding was determined by 
subtracting the amount of nonspecific binding measured in the 
presence of propranolol from the total binding. The maximal 
numbers of binding sites and the dissociation constant were 
calculated by Scatchard's analysis (15). 
Competition curve experiments were carried out using the 
selective betal-antagonist CGP27012A (Ciba-Geigy, Basel, 
Switzerland) as a competing ligand with 16 points in the range 
of 10 10 tool/liter to 10 _3 mol/liter. Adopted concentration of
125I iodocyanopindolol was 200 pmol/liter. Ratios of high and 
low affinities were determined using nonlinear regression 
analysis by a GraphPad Prism program (Intuitive Software for 
Science Inc.) based on Munson and Rodbard's method (16). 
High affinity sites were estimated as betal-adrenoceptors and 
low affinity sites as beta2-adrenoceptors (3,17). 
Assay of adenylyl cyclase activities. Adenylyl cyclase activ- 
ities were determined by radioimmunoassay using the partic- 
ulate fraction of the ventricular myocardium prepared as 
described above (18). Twenty-five microliters of membrane 
preparations, adjusted to 1 mg/ml of protein concentration, 
was added to 225 p~l of reaction medium (50 retool/liter of Tris 
hydrochloride, 2.5 retool/liter of disodium adenosine 5'- 
triphosphate, 5 mmol/liter of magnesium chloride, 1 mmol/liter 
of EGTA, 20 retool/liter of creatine phosphate, 50 U/ml of 
creatinine phosphokinase and 0.8 retool/liter of isobutyl- 
methylxanthine). The reaction mixture was incubated at 25°C 
for 10 rain, and the reaction was stopped by boiling the tubes 
at 100°C for 2 rain. The samples were centrifuged at 6,000g for 
20 rain, and the supernatants were stored at -80°C until the 
assay. The reaction mixture without membrane sample or 
adenosine 5'-triphosphate was used as a blank. The cyclic 
3',5'-adenosine monophosphate (cAMP) level was mea- 
sured according to the method of Steiner et al. (19) using an 
assay kit (Yamasa, Chiba, Japan). Adenylyl cyclase activi- 
ties were expressed as cAMP produced per minute per milli- 
gram of protein. Adenylyl cyclase activities were deter- 
mined under basal conditions and after various stimulants, 
including 10 -5 tool/liter of isoproterenol plus 10 -5 tool/liter 
of 5'-guanylylimidodiphosphate, 10 -5 tool/liter of 5'- 
guanylylimidodiphosphate, 8 x 10 3 tool/liter of sodium fluo- 
ride or 2 × 10 -5 mol/liter of forskolin. 
Data analysis, Total forward stroke and regurgitation vol- 
umes were calculated by digitization of the positive and 
negative components of aortic flow with the use of a digitizer 
(type KD 4300, Graphtec Corp.). Stroke volume was calcu- 
lated by subtraction of regurgitant volume from total forward 
stroke volume. The regurgitant fraction was calculated as 
(regurgitant volume/total forward stroke volume) × 100. 
Statistical analysis. Data were expressed as mean values + 
SD. Changes in plasma norepinephrine content in each group 
were assessed by repeated measures analysis of variance 
(ANOVA). Comparison between two groups was performed 
with an unpaired t test. Comparison among three or more 
different groups was performed by one-way ANOVA and the 
Fisher protected least significant difference test. Statistical 
significance was set at p < 0.05. 
Results 
Plasma norepinephrine. The plasma norepinephrine con- 
centration before the 6-hydroxydopamine or vehicle treatment 
was similar among the four groups (Fig. 1). Increases in the 
plasma norepinephrine concentration 1 week after the opera- 
tion were greater in the vehicle-pretreated aortic regurgitation 
group than in the vehicle-pretreated sham group (p < 0.001). 
In the 6-hydroxydopamine-pretreated shamgroup, the plasma 
norepinephrine concentration tended to be lower after the 
operation; however, in the 6-hydroxydopamine-pretreated 
aortic regurgitation group, it was higher after the operation. 
Changes in the plasma norepinephrine concentration were 
significantly different between the 6-hydroxydopamine- 
pretreated groups (p < 0.01). 
Body weight and left ventricular mass. Body weights were 
lower and left ventricular mass per body weight was higher in 
the aortic regurgitation groups than in the sham groups. There 
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Figure 1. A, Plot of the plasma norepinephrine concentration f 
control animals before (pre) and 1 week after (post) the operation for 
aortic regurgitation (vehicle + AR, solid circles, solid line) or a sham 
operation (vehicle + sham, open circles, dashed line). Increases in the 
plasma norepinephrine concentration n the vehicle + AR group are 
greater than those in the vehicle + sham group (repeated measures 
analysis of variance). B,Plot of the plasma norepinephrine concentra- 
tion of 6-hydroxydopamine (6-OHDA)-treated animals before (pre) 
and 1 week after (post) the operation for aortic regurgitation (6-
OHDA + AR, solid squares, olid line) or a sham operation (6- 
OHDA + sham, open squares, dashed line). In the 6-OHDA + sham 
group, the plasma norepinephrine concentration tended to be de- 
creased after the operation, but was increased after the operation i
the 6-OHDA + AR group. Changes in the plasma norepinephrine 
concentration arc significantly different between the 6-OHDA- 
pretreated groups (repeated measures analysis of variance). 
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were no differences inright ventricular mass between the aortic 
regurgitation groups and the sham groups (Table 1). 
Itemodynamic data. Table 1 also shows the hemodynamic 
data recorded before excising the heart i week after induction 
of aortic regurgitation or sham operation. Between the 6- 
hydroxydopamine-treated groups, aortic systolic pressures in 
the aortic regurgitation group were lower than those in the 
sham group. Aortic diastolic pressures were lower in the aortic 
regurgitation groups than those in the sham groups, although 
there were no differences between the two groups with aortic 
regurgitation. The decrease in aortic diastolic pressure imme- 
diately after production of aortic regurgitation was also com- 
parable between the two groups (16.6 _+ 2.7 vs. 16.3 _+ 
2.6 mm Hg). The regurgitant fraction was similar between the 
vehicle-pretreated and the 6-hydroxydopamine-pretreated 
aortic regurgitation groups (40.5 + 5.7% vs. 41.4 _+ 6.6%). 
Cardiac output was lower and left ventricular diameters were 
larger in both aortic regurgitation groups than in the sham 
groups. End-diastolic pressure in the aortic regurgitation 
groups was higher in the left ventricle, but not in the right 
ventricle, than that recorded in each sham group. 
Myocardial norepinephrine. Myocardial norepinephrine 
concentration was lower in the vehicle-pretreated aortic regur- 
gitation group than in the vehicle-pretreated sham group 
in the left ventricle (p < 0.05), but not in the right ventricle 
(Table 2). Myocardial norepinephrine concentration i  the 
6-hydroxydopamine-pretreated sham group decreased in the 
left ventricle by 80% (p < 0.0005) and by 77% in the right 
ventricle (p < 0.0005), compared with those concentrations 
in the vehicle-pretreated sham group. Between the 6- 
hydroxydopamine-pretreated groups, there were no signif- 
icant differences in both the ventricles. 
geta-adrenoceptor binding studies. Maximal binding sites 
of total beta-adrenoceptors were lower in the vehicle- 
pretreated aortic regurgitation group than in the vehicle- 
pretreated sham group in the left ventricle but not in the right 
ventricle. The total beta-adrenoceptor densities were higher in 
the 6-hydroxydopamine-pretreated sham group than in the 
vehicle-pretreated sham group in both the left and right 
ventricles. In contrast, hese values were markedly lower in the 
6-hydroxydopamine-pretreated aortic regurgitation group 
than in the 6-hydroxydopamine-pretreated shamgroup in 
both the ventricles (Table 2). The dissociation constants for 
iodocyanopindolol were similar among the four groups (left 
ventricle: vehicle plus sham 55 _+ 42, vehicle plus aortic 
regurgitation 71 _+ 33, 6-hydroxydopamine plus sham 67 _+ 35, 
6-hydroxydopamine plus aortic regurgitation 47 _+ 30 pmol/ 
liter; right ventricle: vehicle plus sham 61 _+ 20, vehi- 
cle plus aortic regurgitation 52 _+ 25, 6-hydroxydopamine 
plus sham 65 _+ 22, 6-hydroxydopamine plus aortic regur- 
gitation 72 _+ 62 pmol/liter). 
Subtypes of beta-adrenoceptors. In the vehicle-pretreated 
aortic regurgitation group, beta~-adrenoceptor densities 
were lower than in the vehicle-pretreated sham group in 
the left ventricle but not in the right ventricle. Beta 1- 
adrenoceptor was higher in the 6-hydroxydopamine- 
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Table 1. Left Ventr icular  Mass and Hemodynamic  Characterist ics 
Vehicle + Sham Vehicle + AR 6-OHDA + Sham 6-OHDA + AR 
(n = 8) (n : 8) (n = 8) (n - 8) 
BW (kg) 2.75 + 0.21 2.41 + 0.25* 2.55 _+ (I.33 2.19 _+ 0.26t 
LV weight[BW (g/kg) 0.62 + 0.07 0.90 _+ 0.11" 0.63 _+ 0.08 1.00 _+ 0.15t 
RV weight/BW (g]kg) 0.26 +_ 0.05 0.25 + 0.04 0.24 _+ 0.03 0.26 + 0.04 
Heart rate (beats/min) 231 + 16 215 _+ 22 229 + 29 205 _+ 36 
AoSP (ram Hg) 102 + 14 87 + 1l 101 + 14 81 + 19t 
AoDP (ram Hg) 80 + 16 47 -+ 15' 77 -+ 16 43 + 13t 
LVEDP (ram Hg) 3.5 -+ 3.1 12.4 -+ 5.3* 4.5 + 2.8 14.4 + 6.3+ 
RVEDP (ram Hg) 2.6 -+ 1.8 3.5 + 1.5 2.9 -+ 1.5 3.4 + 1.5 
CO (ml/min per kg) 97 _+ 33 61 _+ 15" 116 _+ 35 60 _+ 24t 
LVEDD (mm) 21.4 _+ 1.5 24.5 + 1.9" 2(I.8 + 1.7 23.6 _+ 2.4t 
LVESD (ram) 19.1 _+ 1.6 21.8 + 2.4* 19.0 _+ 2.1 21.5 _+ 2.1t 
Data are presented as mean value + SD. *p < 0.05, vehicle t AR versus vehicle + sham; tp < 0.05, 6-OHDA + 
AR versus 6-OHDA + sham (analysis of variance). AoDP = aortic diastolic pressure; AoSP = aortic systolic pressure; 
AR = aortic regurgitation: BW = body weight; CO = cardiac output: EDD = end-diastolic diameter; EDP 
end-diastolic pressure; ESD - end-systolic diameter; LV - left ventricle; 6-OHDA - 6-hydroxydopamine: RV right 
ventricle. 
pretreated sham group than in the vehicle-pretreated sham 
group in both the ventricles. Comparing the 6-hydroxydo- 
pamine-pretreated groups, betat-adrenoceptor densities in 
the aortic regurgitation group were lower than those in the 
sham group in both the left and right ventricles. There were 
no differences in beta2-adrenoceptor in these four groups 
(Table 2). An average dissociation constant (ki) value for 
betal-receptor was 4.1 + 1.6 nmol/liter and for beta 2- 
receptor itwas 1.5 _+ 0.7/xmol/liter. There was no significant 
difference in the ki value among the four groups or between 
the left and right ventricles. 
Adenylyl eyclase assays. Figure 2 shows the results of the 
adenylyl cyclase activity assay. Basal adenylyl cyclase activ- 
ities in both ventricles were similar among the four groups. 
Isoproterenol plus 5'-guanylylimidodiphosphate- (p < 
0.05), 5'-guanylylimidodiphosphate- (p < 0.005) and so- 
dium fluoride-stimulated (p < 0.01) adenylyl cyclase activ- 
ities (basal subtracted) were lower in the vehicle-pretreated 
aortic regurgitation group than in the vehicle-pretreated 
sham group in the left ventricle but not in the right ventricle. 
In the 6-hydroxydopamine-pretreated sham group, the 5'- 
guanylylimidodiphosphate-(left v n ricle, p < 0.001; right 
ventricle, p < 0.05) and sodium fluoride-stimulated (left 
ventricle, p < 0.05; right ventricle, p < 0.01) adenylyl cyclase 
activities were lower than in the vehicle-pretreated sham 
group in both ventricles, although there were no differ- 
ences in isoproterenol plus 5'-guanylylimidodiphosphate- 
stimulated adenylyl cyclase activities between the two 
groups in both ventricles. Comparing the 6-hydroxy- 
dopamine-pretreated groups, the isoproterenol plus 5'- 
guanylylimidodiphosphate-(left v ntricle, p < 0.01; right 
ventricle, p < 0.05), 5'-guanylylimidodiphosphate-(left ven- 
tricle, p < 0.05; right ventricle, p < 0.05) and sodium 
fluoride-stimulated (left ventricle, p < 0.01; right ventricle, 
p < 0.05) adenylyl cyclase activities were lower in the aortic 
regurgitation group than in the sham group in both ventri- 
cles. Finally, the forskolin-stimulated a enylyl cyclase activ- 
ities in both ventricles were similar among the four groups. 
Table 2. Myocardial  Norepinephr ine and Beta-Adrenoceptor  
Vehicle + Sham Vehicle + AR 6-OHDA + Sham 6-OHDA + AR 
(n -S )  (n=8)  (n =8)  (n -8 )  
LV 
MNE (ng/g tissue) 1933 - 451 1263 + 459* 385 + 247t 205 + 108 
BetarAR (fmol/mg protein) 28.8 - 4.7 20.3 + 3.9* 43.5 _+ 10.2t 17.6 _+ 4.05 
Beta2-AR (fmol/mg protein) 4.3 + 0.8 4.0 + 1.0 4.1 + 2.0 4.3 + 2.1 
Total beta-AR (fmol/mg protein) 33.1 _+ 4.7 24.3 + 3.8* 47.6 + 10.6t 21.9 + 3.9:~ 
RV 
MNE (ng/g tissue) 2034 z 631 2250 _+ 863 458 _+ 236t 374 _+ 187 
BetarAR (fmol/mg protein) 24.8 _+ 5.7 21.0 _+ 3.7 36.9 _+ 9.8- 13.2 + 5.15 
Beta2-AR (fmol/mg protein) 3.7 _+ 0.6 3.1 + 1.2 3.2 + 1.5 3.1 + 1.6 
Total beta-AR (fmol/mg protein) 28.5 - 6.0 24.1 _+ 4.4 40.1 + 9.7+ 16.3 _+ 6.0~ 
Data presented are mean value + SD. *p < 0.05, vehicle + AR versus vehicle + sham; tp < 0.05, 6-OHDA + sham 
versus vehicle + sham: Sp < 0.05, 6-OHDA + AR versus 6-OHDA + sham (analysis of variance). Beta-AR 
beta-adrenoceptur: MNE = myocardial norepinephrine. Other abbreviations a in Table 1. 
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A pmol/min/mg of protein 
50000j [] Vehicle+ Sham 
[] Vehicle + AR 
40000' 
B pmol/min/mg of protein 
50000 f • Veh ic le+Sham 
[] Vehicle + AR 
40000 
30000 30000" 
20000' 20000' 
10000' 10000" 
0 ~ 
Basal ISP+Gpp(NH)p Gpp(NH)p 
C pmol/min/mg of protein 
50000 -'r 
NaF Forskolin 
40000 
[] 6-OHDA+ Sham 
[]  6-OHDA + AR 
D 
0 ~ 
Basal ISP+Gpp(NHlp Gpp(NH)p NaF Forskolin 
pmol/min/mg ofprotein 
50000-T 
40000 
[] 6-OHDA+Sham 
[] 6-OHDA +AR 
30000" 30000" 
20000 20000 
10000" t I" 
Basal ISP+Gpp(NH)p Gpp(NH)p NaF Forskolin 
LV 
10000 
Basal ISP+Gpp(NH)p Gpp(NH)p 
RV 
NaF Forskolin 
Discuss ion 
Betal-adrenoceptor downregulation and a decrease in G 
protein-mediated a enylyl cyclase activity occurred specifically 
in the failing left ventricle, but not in the nonfailing right 
ventricle, after induction of aortic regurgitation. Chemical 
denervation by 6-hydroxydopamine pretreatment did not 
prevent the alteration of beta-adrenergic signaling in the 
failing myocardium. In contrast, chemical denervation by 
6-hydroxydopamine caused a marked decrease in beta- 
adrenoceptor densities and G protein-mediated a enylyl cy- 
clase activity in the nonfailing right ventricle as well as in the 
failing left ventricle, The chamber-specific alteration of beta- 
adrenergic signaling after induction of acute left ventricular 
failure was abolished by sympathetic denervation. 
Features of chemical denervation using 6-hydroxydopamine. 
Chemical denervation using 6-hydroxydopamine can produce 
selective sympathetic denervation, whereas urgical denerva- 
tion or heart transplantation cannot avoid parasympathetic 
denervation (9). Histochemical examination shows marked 
depletion of catecholamine-containing nerve terminals after 
Figure 2. Bar graphs of adenylyl cyclase activities (pmol/min per mg of 
protein) from the left (LV) and right ventricle (RV) of vehicle or 
6-hydroxydopamine-treated nimals that underwent a sham (vehi- 
cle + sham, 6-OHDA + sham) or operative procedure for aortic 
regurgitation (vehicle + AR, 6-OHDA + AR). Data represent cyclic 
AMP produced in pmol/mg per min _+ SD and are net values (basal 
subtracted) under stimulation with 10 5 tool/liter isoproterenol +10 s 
tool/liter 5'-guanylylimidodiphosphate (ISP + Gpp(NH)p); 10 s tool/ 
liter Gpp(NH)p; 8 × 10 3 tool/liter sodium fluoride (NaF); and 2 × 
10 s tool/liter of forskolin. A, Adenylyl cyclase activity in the left 
ventricle significantly differs (*p < 0.05) between the vehicle + sham 
and vehicle + AR groups after stimulation with isoproterenol + 
Gpp(NH)p, Gpp(NH)p and NaF. B, Adenylyl cyclase activity in the 
right ventricle does not differ under these conditions. C, D, Adenylyl 
cyclase activity in both the left and right ventricles ignificantly differs 
(p < 0.05) between the 6-OHDA + sham and 6-OI-IDA + All groups 
after stimulation with isoproterenol + Gpp(NH)p, Gpp(NH)p and NaF. 
6-hydroxydopamine tr atment (20). Himura et al. (6) have 
shown that a similar loss of noradrenergic nerve terminals 
occurred in failing myocardium, as evidenced by the reduc- 
tion of catecholaminergic histofluorescence- and tyrosine 
hydroxylase-immunostained profiles. Daly and Sole (21) hy- 
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pothesized that the production of 6-hydroxydopamine-like 
toxic metabolites may destroy the sympathetic nerve terminals 
in the failing myocardium, based on their following findings. 
Incessant hyperactivity in sympathetic nerve terminals leads to 
a decrease in norepinephrine and an increase in dopamine 
(22). High levels of neuronal dopamine found in such circum- 
stances are present in the extravesicular space and are thus 
relatively unprotected (23). Such stores may be susceptible to 
oxidation, leading to the production of 6-hydroxydopamine, a 
potent neurotoxin that causes autodestruction f the nerve 
terminal. 
Beta.adrenergic signaling in denervated myocardium. 
Sympathetic denervation causes a supersensitivity to exoge- 
nous catecholamines. Alterations in the postreceptor mecha- 
nisms of denervated myocardium remain to be determined. 
Vatner et al. (24) observed that isoproterenol plus 5'- 
guanylylimidodiphosphate- and sodium fluoride-stimulated 
maximal adenylyl cyclase activities tended to be lower in 
surgically denervated ogs than in control dogs, although 
l-[3H]dihydroalprenolol binding sites were higher, and median 
effective concentration (ECs0) for isoproterenol-stimulated 
adenylyl cyclase activity and muscarinic receptor density was 
lower in the denervated dogs. Studies on cardiac denervation 
after transplantation also supported these findings (25-27). 
Recently, Loh et al. (28) reported that guanine nuclcotide- 
stimulated adenylyl cyclase activity was decreased in parallel 
with decreased levels of Gs~ protein and its messenger RNA 
after orthotopic ardiac transplantation. 
In experimental studies using chemical denervation, Pik 
and Wollemann (29) observed beta-adrenoceptor up egulation 
and an increase in norepinephrine- and isoproterenol- 
stimulated adcnylyl cyclase activity in denervated rat heart 2 h 
after the administration of 6-hydroxydopamine. Chiu also 
found that norepinephrine-, isoproterenol-, sodium fluoride- 
and 5'-guanylylimidodiphosphate-stimulated adenylyl cyclase 
activities were enhanced in the 6-hydroxydopamine-treated rat 
myocardium, and suggested that the enhancement of the signal 
transduction pathway was related to the denervation supersen- 
sitivity, although beta-adrenoceptor binding assays were not 
performed (30). However, recent findings are unexpectedly in 
contrast o these classic findings. Hammond et al. (31) re- 
ported that 6-hydroxydopamine administration during the 
neonatal phase induced ownregulation f beta-adrenoceptors 
and a decrease in isoproterenol-, 5'-guanylylimidodiphosphate- 
and sodium fluoride- but not manganese-stimulated adenylyl 
cyclase activities in the sinoatrial node and right atrium, despite 
an increased chronotropic response to isoproterenol and tread- 
mill exercise testing. These discrepant results may be related to 
species differences, age differences or differences in the protocols 
for sympathetic denervation. 6-Hydroxydopamine also has an 
acute toxic effect owing to the release of norepinephrine, in 
addition to its substantial effect of sympathetic denervation. 
The change in beta-adrenergic signaling immediately after 
6-hydroxydopamine injection may therefore be different from 
that observed in the long-term phase of 6-hydroxydopamine 
treatment. 
Preliminary finding from our laboratory revealed that ino- 
tropic responsiveness to dobutamine, as determined by 
measurement of peak positive left ventricular dP/dt, was in- 
creased in rabbits with 6-hydroxydopamine tr atment. However, 
isoproterenol plus 5'-guanylylimidodiphosphate-stimulated ad- 
enylyl cyclase activities were not increased, possibly because of the 
combined effects of upregulation of beta-adrenoceptor and the 
decrease in G protein-mediated a enylyl cyclase activities, 
suggesting that catecholamine supersensitivity was related to a 
postreceptor mechanism not linked to cAMP production. 
These findings are consistent with recent findings that showed 
G-protein-mediated a enylyl cyclase activity was attenuated in
denervated myocardium (24,25,27,31). It is possible that sym- 
pathetic innervation may regulate G-protein levels indepen- 
dently from beta-adrenoceptor density, in a manner similar to 
the relation between sympathetic nnervation and expression 
of calcium channels densities (32). 
Alteration of beta-adrenergic signaling in failing myocar- 
dium. In the present study, a decrease in beta-adrenoceptor 
densities and G protein-mediated a enylyl cyclase activities was 
observed specifically in the failing ventricle. However, forskolin- 
stimulated adenylyl c3~clase activity was not reduced in the failing 
ventricle, which suggested that a catal~ic unit of adenylyl cyclase 
was preserved. This finding is in contrast o the previous tudy in 
patients with primary pulmonary hypertension, in which 
forskolin- and manganese-stimulated adenylyl cydase activities, 
as well as 5'-guanylylimidodiphosphate-stimulated adenylyl cy- 
clase activities, were decreased in the failing right ventricle. The 
discrepancies may be related to the severity of heart failure, the 
period of morbidity, or the therapeutic interventions. In the 
clinical studies, failing hearts were obtained from patients who 
underwent cardiac transplantation after they had suffered from 
protracted heart failure. The morbidity period of the animal 
model used in the present study was shorter than that found with 
the human failing heart. In the animal model for chronic right 
ventricular failure produced by progressive pulmonary artery 
constriction and tricuspid avulsion, forskolin- as well as 
isoproterenol- and 5'-guanylylimidodiphosphate-stimulated ad- 
enylyl cyclase activities were significantly decreased, although 
manganese-stimulated activities were preserved (33). It is possible 
that the beta-adrenergic signal transduction pathway is more 
profoundly affected in chronic heart failure than in acute left 
ventricular failure. 
The attenuation of both 5'-guanylylimidodiphosphate- and 
sodium fluoride-stimulated a enylyl cyclase activities indicates 
that a change in the amount or function of Gs~ occurred, 
although we do not have any direct evidence of the change in 
Gs~. Although it is generally agreed that Gs,~ is not changed in 
human heart failure, animal experiments showed that either 
the amount or function or messenger RNA levels for Gs was 
decreased, as stated in a recent review (34). Our findings are 
consistent with previous tudies in animal models. 
Relation between sympathetic innervation and chamber- 
specific alteration of beta-adrenergic signaling in heart fail- 
ure. Diverse interstitial norepinephrine concentration is pre- 
sumed to be the most plausible mechanism leading to the 
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chamber-specific downregulation of beta-adrenoceptor. Nor- 
epinephrine concentration in local sympathetic left is deter- 
mined by three factors: 1) circulating levels of norepinephrine 
that can diffuse into the interstitium, 2) the rate of release of 
norepinephrine into the interstitium from cardiac sympathetic 
neurons, and 3) the rate of reuptake of norepinephrine by the 
neuronal terminals (4). The circulating level of norepinephrine 
that is required for beta-adrenoceptor downregulation in the 
intact heart in vivo is much higher than that seen in heart 
failure. Vatner et al. (35) failed to demonstrate beta- 
adrenoceptor downregulation in chronic norepinephrine infu- 
sion models in which the plasma norepinephrine level ex- 
ceeded the control level by more than 15 times. 
If the cause of chamber specificity is a local increase 
of norepinephrine release, the administration of 6- hydroxy- 
dopamine would inhibit the downregulation of beta- 
adrenoceptors. Alternatively, if the local decrease of norepi- 
nephrine reuptake is responsible for chamber specificity, 
6-hydro~dopamine administration could facilitate beta- 
adrenoceptor downregulation. In the present study, myocar- 
dial denervation and induction of aortic regurgitation facili- 
tated the downregulation of beta-adrenoceptor in the 
nonfailing right ventricle as well as in the failing left ventricle. 
These results suggest hat a defect of neuronal reuptake in the 
failing ventricle may be responsible for the chamber-specific 
regulation of beta-adrenergic signaling in heart failure. 
Chamber-specific abnormalities of the neuronal norepi- 
nephrine reuptake mechanism have been previously described 
using an experimental model for right ventricular failure (5,6). 
These investigators reported that local neuronal norepineph- 
rine uptake activity and tissue norepinephrine content were 
decreased. In addition, noradrenergic nerve terminals them- 
selves were lost from the failing ventricle, as evidenced by 
tyrosine hydroxylase immunocytochemical staining. The re- 
uptake mechanism at the synaptic nerve terminals maintains a 
low level of norepinephrine at the postjunctional beta- 
adrenoceptor. When the reuptake mechanism is disturbed, the 
beta-adrenoceptors might be easily downregulated by the local 
increase in norepinephrine concentration. Intact sympathetic 
innervation in nonfailing myocardium may exert a protective 
effect against the downregulation of beta-adrenoceptor. 
Conclusions. Sympathetic denervation using 6- 
hydroxydopamine abolished the chamber-specific alterations 
in beta-adrenergic signaling in rabbits with heart failure. Local 
loss of sympathetic nerve endings, especially the defect of 
neuronal norepinephrine uptake, is likely to be responsible for 
the chamber-specific downregulation of beta-adrenoceptor. 
Such local denervation may also affect postreceptor, G- 
protein-mediated signaling. 
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